Is Cancer a Metabolic Disease?

Slides:

Advertisements

Similar presentations

Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.

Advertisements

Gene Preference in Maple Syrup Urine Disease Mary M. Nellis, Dean J. Danner The American Journal of Human Genetics Volume 68, Issue 1, Pages (January.

Lactate Lactate dehydrogenase Pyruvate + NADH ATP Pyruvate carboxylase ADP Oxaloacetate GTP phosphoenolpyruvate carboxykinase GDP Phosphoenol pyruvate.

WE Presentation #3, Lee et al Cell, “A Lactate-Induced Response to Hypoxia” 2015.

Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling Gavin J.

Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification.

CC Chemokine Receptor 5 and CXC Chemokine Receptor 6 Expression by Lung CD8+ Cells Correlates with Chronic Obstructive Pulmonary Disease Severity Christine.

Telomerase Activity and Expression of Telomerase RNA Component and Telomerase Catalytic Subunit Gene in Cervical Cancer Kenji Nakano, Elizabeth Watney,

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Enterococcus faecalis Induces Inflammatory Bowel Disease in Interleukin-10 Knockout Mice Edward Balish, Thomas Warner The American Journal of Pathology.

High Expression of Sphingosine 1-Phosphate Receptors, S1P1 and S1P3, Sphingosine Kinase 1, and Extracellular Signal-Regulated Kinase-1/2 Is Associated.

Figure 1. The variation of pressure in SF.

Cristoforo Grasso, Gerrit Jansen, Elisa Giovannetti

Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich

Allison A. Madigan, Kevin J. Rycyna, Anil V. Parwani, Yeipyeng J

Triple-Negative Breast Cancer

Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers Rebecca A. Betensky, Catherine.

Sirt4: The Glutamine Gatekeeper

Volume 56, Issue 3, Pages (November 2014)

Volume 199, Issue 1, (January 2018)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Nephrol. doi: /nrneph

Joanna Wang, Chetan Bettegowda The Journal of Molecular Diagnostics

Cell signaling and cancer

Peter W. Szlosarek, SukJun Lee, Patrick J. Pollard Molecular Cell

Figure 1 Control of hepatic gluconeogenesis

Shining light on vitamin D trials in chronic kidney disease

Volume 148, Issue 3, (February 2012)

The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests Susan J. Hsiao, Mahesh M. Mansukhani,

You Down With ETC? Yeah, You Know D!

Muscle Fatigue from Losing Your PHD

William L. Gerald, M.D., Ph.D, 1954–2008

Shane Rea, Thomas E. Johnson Developmental Cell

A, diagram depicting receptor signaling and nutrient import.

The Quid Pro Quo of the Tumor/Stromal Interaction

Understanding the Intersections between Metabolism and Cancer Biology

Use of Closely Related Affected Individuals for the Genetic Study of Complex Diseases in Founder Populations C. Bourgain, E. Génin, P. Holopainen, K.

When Cancer Cells Are Given Lemo[NH3]s, They Make Lemo[NH3]ade

Joseph A. Baur, Morris J. Birnbaum Cell Metabolism

Metabolic reprogramming in the hypoxic microenvironmentThis figure shows the metabolic processes that are upregulated in response to hypoxia and the therapeutic.

Keiran S.M. Smalley Journal of Investigative Dermatology

Metabolic Regulation of the Immune Humoral Response

Metabolic Flux and the Regulation of Mammalian Cell Growth

Tumor Cell Metabolism: Cancer's Achilles' Heel

Role of Endothelial Cell Metabolism in Vessel Sprouting

Cancer Metabolism: Is Glutamine Sweeter than Glucose?

Targeting Bacterial Central Metabolism for Drug Development

Waste Not, Want Not: Lactate Oxidation Fuels the TCA Cycle

Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich

Gabriela Andrejeva, Jeffrey C. Rathmell Cell Metabolism

Erratum The American Journal of Human Genetics

Single-Gene Disorders: What Role Could Moonlighting Enzymes Play?

John D. Gordan, Craig B. Thompson, M. Celeste Simon Cancer Cell

Volume 7, Issue 1, Pages (January 2008)

J. Enrique Salcedo-Sora, Eva Caamano-Gutierrez, Stephen A

Society for Investigative Dermatology 2010 Meeting Minutes

Muscle Fatigue from Losing Your PHD

MYC-regulated metabolic pathways in cancer.

Volume 70, Issue 11, Pages (December 2006)

Genetics of hepatocellular carcinoma: The next generation

Serine Metabolism: Some Tumors Take the Road Less Traveled

Activation of B-raf in Non-Malignant Nevi Predicts a Novel Tumor Suppressor Gene in Melanoma (MAP Kinase Phosphatase) Jack L. Arbiser Journal of Investigative.

Scheme 2: Interaction between glycolysis and mitochondrial reactions.

PK-M2 Makes Cells Sweeter on HIF1

Paradoxical Effects of Sphingosine-1-Phosphate

Christopher D. Wiley, Judith Campisi Cell Metabolism

The Mitochondrial Pyruvate Carrier: Has It Been Unearthed at Last?

Main metabolic pathways deregulated in cancers and corresponding targeting drugs. Main metabolic pathways deregulated in cancers and corresponding targeting.

Volume 7, Issue 1, Pages (January 2008)

Proliferating Cells Conserve Nitrogen to Support Growth

Presentation transcript:

Is Cancer a Metabolic Disease? Hilary A. Coller The American Journal of Pathology Volume 184, Issue 1, Pages 4-17 (January 2014) DOI: 10.1016/j.ajpath.2013.07.035 Copyright © 2014 American Society for Investigative Pathology Terms and Conditions

Figure 1 Cancer metabolism. Scheme shows central carbon metabolism. Metabolic reactions that tend to be faster in tumors are identified in red, whereas reactions that tend to be slower in tumors are identified in green. DHAP, dihydroxyacetone phosphate; GAP, glyceraldehyde 3-phosphate; KG, α-ketoglutarate; OAA, oxaloacetate; PEP, phosphoenolpyruvate. The American Journal of Pathology 2014 184, 4-17DOI: (10.1016/j.ajpath.2013.07.035) Copyright © 2014 American Society for Investigative Pathology Terms and Conditions

Figure 2 Metabolic approaches to treating cancer. Scheme shows some of the compounds being explored as anticancer agents and the metabolic reactions that they target. Red lines indicate inhibition; green lines, activation. BPTES, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide; DHAP, dihydroxyacetone phosphate; GAP, glyceraldehyde 3-phosphate; GLS, glutamine synthetase; GOT, glutamate oxaloacetate transaminase; HK, hexokinase; MCT, monocarboxylate transporters; OAA, oxaloacetate; PD, pyruvate dehydrogenase; PEP, phosphoenolpyruvate; PK, pyruvate kinase. The American Journal of Pathology 2014 184, 4-17DOI: (10.1016/j.ajpath.2013.07.035) Copyright © 2014 American Society for Investigative Pathology Terms and Conditions

Figure 3 Metabolic effects of oncogenes and tumor suppressors. Scheme shows the metabolic reactions in central carbon metabolism affected by AKT (orange), MYC (blue), HIF (green) and p53 (red). Arrows indicate activation; lines, repression. DHAP, dihydroxyacetone phosphate; GAP, glyceraldehyde 3-phosphate; GDH, glutamate dehydrogenase; GLS, glutamine synthetase; HK, hexokinase; KG, α-ketoglutarate; LDH, lactate dehydrogenase; OAA, oxaloacetate; PEP, phosphoenolpyruvate. The American Journal of Pathology 2014 184, 4-17DOI: (10.1016/j.ajpath.2013.07.035) Copyright © 2014 American Society for Investigative Pathology Terms and Conditions